New Delhi: Rising research and development initiatives in the pharma sector has made India a more mature place for drug discovery activities than China, says a report.
Further, the report prepared by US-based Ewing Marion Kauffman Foundation noted Indian companies are playing a strategic role in early drug discovery processes due to their vast experience in the field of generic drugs.
India is regarded as a more mature venue for chemistry and drug discovery activities than China, the study titled ‘The globalisation of innovation: Pharmaceuticals, Can India and China cure the Global Pharmaceutical Market?´ said.
Companies like Aurigene, Advinus, Nicholas Piramal and Jubilant have negotiated long-term deals with foreign pharma firms for developing new chemical entities.
“Several drugs from these partnerships are going into clinical testing. As a result, the trend of R&D moving to these countries is likely to gain further momentum,” the study added.
Another benefit from the rising R&D activities has been that both Indian and Chinese scientists are fast developing the ability to innovate and create their own intellectual property.